Drug Profile

Parathyroid hormone receptor type 1 agonist - Confo Therapeutics

Alternative Names: PTH1R agonist - Confo Therapeutics

Latest Information Update: 10 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Jul 2024 Confo Therapeutics has patent protection for Confo® technology platform in more than 10 patent families worldwide, prior to July 2024 (Confo Therapeutics website, July 2024)
26 Jul 2024 Early research in Hypoparathyroidism in China (unspecified route),prior to July 2024 (Confo Therapeutics pipeline, July 2024)
15 Dec 2021 Confo Therapeutics has patent protection for methods for screening GPCRs using ConfoBodies®, GPCR-ConfoBody® complexes, developments of the ConfoBody® platform in ConfoScreen®, ConfoSensor®, ConfoChimer™ and ConfoStructure™ technologies in USA and European Union

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com